Enliven Therapeutics, Inc. (ELVN) stock
ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$44.89−1.96 (-4.18%)
Close on Nov 18, 2026Market cap $3.29BP/E –Yield –
Enliven Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Enliven Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$124.41M. For fiscal 2025 it was -$119.66M. The highest annual figure on record is -$24.12M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$119.66M | – |
| FY2024 | Dec 31, 2024 | -$104.55M | – |
| FY2023 | Dec 31, 2023 | -$83.53M | – |
| FY2022 | Dec 31, 2022 | -$38.79M | – |
| FY2021 | Dec 31, 2021 | -$51.44M | – |
| FY2020 | Dec 31, 2020 | -$41.70M | – |
| FY2019 | Dec 31, 2019 | -$24.12M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$37.21M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.82M | – |
| Q4 FY2025 | Dec 31, 2025 | -$34.29M | – |
| Q3 FY2025 | Sep 30, 2025 | -$25.10M | – |
| Q2 FY2025 | Jun 30, 2025 | -$28.58M | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.69M | – |
| Q4 FY2024 | Dec 31, 2024 | -$26.90M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.07M | – |
| Q2 FY2024 | Jun 30, 2024 | -$24.60M | – |
| Q1 FY2024 | Mar 31, 2024 | -$25.99M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.73M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.25M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.13M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.42M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.16M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.93M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.02M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.68M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.33M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.66M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.17M | – |
| Q1 FY2021 | Mar 31, 2021 | -$10.28M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.55M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.49M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.30M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.35M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.48M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.88M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.56M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.19M | – |
See a number that looks wrong?